NL-OMON31459已完成3 期
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/A
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •-written informed consent
- •-aged 18 to 55 years old
- •-confirmed diagnosis of relapsing-remitting multiple sclerosis
- •-baseline EDDS between 0.0 and 5.0 inclusive (expanded disability status scale)
- •-must have experienced at least 1 relapse within the 12 months prior to randomization
排除标准
- •-primary progressive, secondary progressive, or progressive elapsing MS
- •-unable to perform the Timed 25-Foot Walk, Nine-Hole Peg Test (9HTP) with both upper extremities, and PASAT 3
- •-unable to perform visual function tests
- •-history of malignancy
- •-history of severe allergic of anaphylactic reactions or known drug hypersensitivity
研究者
相似试验
进行中（未招募）
1 期
A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase 3 Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine - RAINBOWMetastatic gastric or gastroesophageal adenocarcinomaMedDRA version: 12.1Level: LLTClassification code 10063916Term: Metastatic gastric cancerEUCTR2010-020426-18-ROImClone LLC665
进行中（未招募）
1 期
A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.Pulmonary Arterial HypertensionEUCTR2019-002817-21-SEActelion Pharmaceuticals Ltd.237
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - DEFINEEUCTR2006-003696-12-BGBiogen Idec Ltd.1,011
进行中（未招募）
1 期
A study to see if it is safe and helpful to add Selexipag to other PAH medication in children and adolescents.Pulmonary Arterial HypertensionEUCTR2019-002817-21-DEActelion Pharmaceuticals Ltd.237
进行中（未招募）
不适用
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis - N/ARelapsing-Remitting Multiple SclerosisMedDRA version: 8.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2006-003696-12-CZBiogen Idec Ltd.1,011